University of Massachusetts Medical School granted H. Lundbeck's Lundbeck Inc. subsidiary an option to develop RNAi-based therapies to treat Huntington's disease discovered at UMass

University of Massachusetts Medical School

U.S. / Academic

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

H. Lundbeck A/S

Denmark / Mid-Cap Biopharma ($1-$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced